CSIMarket Company Name, Ticker, Suppliers, else..
 
Vaxart Inc   (VXRT)
Other Ticker:  
 
 
Price: $0.5992 $-0.01 -1.770%
Day's High: $0.6249 Week Perf: -1.41 %
Day's Low: $ 0.58 30 Day Perf: -28.25 %
Volume (M): 1,321 52 Wk High: $ 1.54
Volume (M$): $ 791 52 Wk Avg: $0.83
Open: $0.62 52 Wk Low: $0.52



 Market Capitalization (Millions $) 136
 Shares Outstanding (Millions) 227
 Employees -
 Revenues (TTM) (Millions $) 17
 Net Income (TTM) (Millions $) -72
 Cash Flow (TTM) (Millions $) -11
 Capital Exp. (TTM) (Millions $) 1

Vaxart Inc
Vaxart Inc is a biotechnology company that specializes in the development of oral vaccines. They focus on creating vaccines using their proprietary oral tablet vaccine platform instead of the traditional injection-based vaccines. Vaxart's technology allows for the development of vaccines that are easier to administer, more patient-friendly, and potentially more effective. They primarily target infectious diseases, such as the flu, norovirus, and respiratory syncytial virus (RSV), but their platform has the potential to be applied to other diseases as well. The company also collaborates with pharmaceutical partners and government organizations for the development and commercialization of their vaccine candidates.


   Company Address: 170 Harbor Way, Suite 300 South San Francisco 94080 CA
   Company Phone Number: 550-3500   Stock Exchange / Ticker: NASDAQ VXRT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALEC   -29.3%    
ELUT   -8.68%    
MRNA        13.83% 
NVAX        8.56% 
STRO   -2.62%    
VIR        13.06% 
• View Complete Report
   



Shares

Vaxart, Inc. Lures Talent with Equity Awards Amidst Share Price Struggles

Published Tue, Nov 19 2024 1:00 PM UTC

In a strategic move to attract top talent, Vaxart, Inc. (Nasdaq: VXRT) announced on November 19, 2024, that its Compensation Committee has granted inducement equity awards, totaling 91,500 shares of common stock. These awards were given to two new non-executive employees, aimed at inducing them to join the ranks of Vaxart. This decision aligns with Nasdaq Listing Rule 5635(c...
Clinical Study

Navigating Clinical Advancements and Financial Realignment Vaxart Initiates Phase 2b Evaluation of Oral COVID-19 Vacc...

Published Mon, Sep 30 2024 8:13 PM UTC

Evaluation of Vaxart s Next-Generation Oral COVID-19 Vaccine: Initiation of Phase 2b Sentinel CohortVaxart Inc. has recently announced the commencement of the 400-subject sentinel cohort for its Phase 2b study, designed to scrutinize the safety, immunogenicity, and efficacy of its novel oral pill COVID-19 vaccine candidate, when juxtaposed against an approved mRNA vaccine c...
Shares

Vaxart, Inc. Employs Strategic Inducement Grants as Part of its Talent Acquisition Strategy: Continues to Strengthen Workforce Amidst Growing Biotech IndustryConclusion:Vaxart, Inc's recent grant of inducement equity awards to new non-executive employees highlights the company's commitment to attracting and retaining exceptional talent. By leveraging Nasdaq Listing Rule 5635(c)(4), Vaxart offers compelling incentives to highly skilled professionals, enabling the company to strengthen its workforce and accelerate its mission of developing innovative biotechnological solutions.,

Published Fri, Aug 30 2024 12:00 PM UTC


Promoting Talent Acquisition:
The Compensation Committee of Vaxart s Board of Directors, responsible for overseeing compensation and benefits, believes that attracting and retaining exceptional employees is vital to the company s success. In line with this strategy, the committee granted a total of 32,250 shares of Vaxart s common stock to two new non-executive empl...
Financing Agreement

Vaxart Announces $40 Million Underwritten Offering of Common Stock as Tangible Leverage Ratio Shows Positive Improvement

Published Thu, Jun 13 2024 11:08 PM UTC



In a recent announcement, Vaxart, Inc. unveiled plans for an underwritten offering of 50,000,000 shares of its common stock at an offering price of $0.80 per share. The gross proceeds from this offering are expected to reach $40 million. This significant move reflects the growing confidence in Vaxart's potential and its ability to generate investor interest. Additi...
Clinical Study

Vaxart, a dynamic player in the innovative field of vaccine development, has recently announced a significa...

Published Thu, Jun 13 2024 8:15 PM UTC

Vaxart Awarded Up to $453 Million by BARDA for Groundbreaking Phase 2b Study on COVID-19 Oral Pill Vaccine'Vaxart, a dynamic player in the innovative field of vaccine development, has recently announced a significant milestone in its quest to mitigate the global impact of COVID-19. The company has been awarded a Project NextGen fund by the Biomedical Advanced Research and De...






Vaxart Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com